Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) - Related Studies

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

This study has been completed.

Study NCT00093990. Last updated on September 19, 2008. Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Acute Myeloid Leukemia

2	Additional conditions recognized in this trial
		Leukemia
		Leukemia, Myeloid
		Leukemia, Myeloid, Acute

3	More general conditions related to this trial
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		Tipifarnib;Zarnestra; R115777

5	Additional drug interventions recognized in this trial
		Tipifarnib

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		Johnson &Johnson Pharmaceutical Research &Development, L.L.C.